Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Santoian

Interventional Cardiology Ocala, FL Medical Doctor

NPI 1285739425 CMS profile 13233

125 Sw 11Th St, Ocala, FL 34471

Open in the dashboard

General payments

$3,360

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Santoian of Ocala, FL is reported in the CMS Open Payments database as having received $3,360 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 29th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $274 10
2024 General $598 18
2023 General $376 13
2022 General $806 13
2021 General $433 9
2020 General $189 15
2019 General $684 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Santoian
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Edward Santoian were reported at $274. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Edward Santoian Interventional Cardiology median Middle half National median
2019 $684 $1,097 $329–$3,048 $163
2020 $189 $473 $161–$1,480 $114
2021 $433 $677 $233–$1,827 $132
2022 $806 $978 $333–$2,724 $149
2023 $376 $1,136 $382–$2,986 $160
2024 $598 $1,181 $395–$3,326 $164
2025 $274 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $957 7 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $500 34 payments
  3. Inari Medical, Inc. $355 3 payments
  4. Boston Scientific Corporation $246 14 payments
  5. Kestra Medical Technology Services, Inc. $218 14 payments
  6. Medtronic, Inc. $216 8 payments
  7. Impulse Dynamics (USA) Inc. $214 2 payments
  8. Edwards Lifesciences Corporation $183 1 payment
  9. Cardiovascular Systems Inc. $173 2 payments
  10. AstraZeneca Pharmaceuticals LP $124 1 payment
  11. Other $172 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,331 95 payments
  2. Long term medical supply or device loan $28 1 payment
Products named General payments · program years 2019–2025
  1. Impella $846 6 payments
  2. LifeVest $500 34 payments
  3. FLOWTRIEVER CATHETER, S $382 4 payments
  4. CT THROMBECTOMY SYSTEM KIT $329 2 payments
  5. Assure WCD $218 14 payments
  6. Optimizer Smart System $214 2 payments
  7. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $183 1 payment
  8. Diamondback Coronary $173 2 payments
  9. Diamondback Peripheral $173 2 payments
  10. LOKELMA $124 1 payment
  11. Other $634 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

426

Median for Interventional Cardiology: 2,236

Drug cost

$19,335

Median for Interventional Cardiology: $380,412

Branded share of claims

65.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 23 $12,707
Prasugrel Hcl Generic 48 $3,920
Clopidogrel Clopidogrel Bisulfate Brand 255 $1,938
Atorvastatin Calcium Generic 87 $671
Metoprolol Succinate Generic 13 $99

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$83,360

Medicare's payments for the services billed

Medicare patients

207

Average age 75

Services billed

680

100 women, 107 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Diabetes 60%
Heart failure 52%
Arthritis 52%
Chronic kidney disease 50%
Atrial fibrillation 38%
COPD 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record